Cabaletta Bio
CABA
61 hedge funds and large institutions have $211M invested in Cabaletta Bio in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 12 closing their positions.
218% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $445K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
56% more capital invested
Capital invested by funds: $135M → $211M (+$75.8M)
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
7.7% more ownership
Funds ownership: 76.4% → 84.1% (+7.7%)
3% less funds holding
Funds holding: 63 → 61 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.81M |
| 3 |
SC
Samlyn Capital
New York
|
+$3.22M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.79M |
| 5 |
O
OrbiMed
New York
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.01M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$5.76M |
| 3 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$395K |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$309K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$307K |
CABA Hedge Fund Activity: Q3 2021 in Review
61 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q3 2021, worth a combined $211M — up 56% from $135M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CABA and 10 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 19 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $8.3M. The largest seller was Millennium Management, cutting an estimated $8.01M.
- 61 institutional investors held Cabaletta Bio (CABA) as of Q3 2021, down from 63 in Q2 2021.
- Funds reported $211M of Cabaletta Bio stock for Q3 2021, up 56% quarter-over-quarter.
- 10 funds opened new Cabaletta Bio positions in Q3 2021 and 12 closed out, a net change of -2 holders.
- The largest Cabaletta Bio buyer in Q3 2021 was Point72 Asset Management, an estimated $8.3M added.
- The largest Cabaletta Bio seller in Q3 2021 was Millennium Management, an estimated $8.01M sold.
Based on aggregated 13F filings for Q3 2021.